Real world incidence and management of adverse events in patients with HR+, HER2− metastatic breast cancer receiving CDK4 and 6 inhibitors in a United States community setting

References

• American Cancer Society. Cancer facts and figures. Atlanta (GA): American Cancer Society, Inc; 2021.
   Google Scholar
• Paraskevi T. Quality of life outcomes in patients with breast cancer. Oncol Rev. 2012;6(1):e2.
   PubMedGoogle Scholar
• Reich M, Lesur A, Perdrizet-Chevallier C. Depression, quality of life and breast cancer: a review of the literature. Breast Cancer Res Treat. 2008;110(1):9–17.
   PubMed Web of Science ®Google Scholar
• O’Shaughnessy J. Extending survival with chemotherapy in patients with breast cancer. Oncologist. 2005;10(S3):20–29.
   PubMed Web of Science ®Google Scholar
• National Cancer Institute. Surveillance, epidemiology and end of results program. Female breast cancer. (accessed 2021 Sep 30). Available from: https://seer.cancer.gov/statfacts/html/breast.html
   Google Scholar
• National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines), breast cancer (version 1). 2022 (accessed 2021 Nov 24). Available from: https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf
   Google Scholar
• Cristofanilli M, Turner NC, Bondarenko I, et al. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. Lancet Oncol. 2016;17(4):425–439.
   PubMed Web of Science ®Google Scholar
• Dickler MN, Tolaney SM, Rugo HS, et al. MONARCH 1, a phase II study of abemaciclib, a CDK4 and CDK6 inhibitor, as a single agent, in patients with refractory HR+/HER2- metastatic breast cancer. Clin Cancer Res. 2017;23(17):5218–5224.
   PubMed Web of Science ®Google Scholar
• Finn RS, Martin M, Rugo HS, et al. Palbociclib and letrozole in advanced breast cancer. N Engl J Med. 2016;375(20):1925–1936.
   PubMed Web of Science ®Google Scholar
• Goetz MP, Toi M, Campone M, et al. MONARCH 3: abemaciclib as initial therapy for advanced breast cancer. J Clin Oncol. 2017;35(32):3638–3646.
   PubMed Web of Science ®Google Scholar
• Hortobagyi GN, Stemmer SM, Burris HA, et al. Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer. Ann Oncol. 2018;29(7):1541–1547.
   PubMed Web of Science ®Google Scholar
• Sledge J,. GW, Toi M, Neven P, et al. MONARCH 2: abemaciclib in combination with fulvestrant in women with HR+/HER2− advanced breast cancer who had progressed while receiving endocrine therapy. J Clin Oncol. 2017;35(25):2875–2884.
   PubMed Web of Science ®Google Scholar
• Tripathy D, Im S-A, Colleoni M, et al. Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial. Lancet Oncol. 2018;19(7):904–915.
   PubMed Web of Science ®Google Scholar
• Dhillon S. Palbociclib: first global approval. Drugs. 2015;75(5):541–543.
   Web of Science ®Google Scholar
• Kim ES. Abemaciclib: first global approval. Drugs. 2017;77(18):2063–2070.
   PubMed Web of Science ®Google Scholar
• Syed YY. Ribociclib: first global approval. Drugs. 2017;77(7):799–807.
   PubMed Web of Science ®Google Scholar
• VERZENIO® [label]. Indianapolis (IN): Eli Lilly and Company; 2017 (accessed 2022 Jan 31). Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/208716s006s007s008lbl.pdf
   Google Scholar
• IBRANCE® [label]. New York (NY): Pfizer Laboratories Div Pfizer Inc; 2015 (accessed 2022 Jan 31). Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/207103s008lbl.pdf
   Google Scholar
• KISQALI® [label]. East Hanover (NJ): Novartis Pharmaceuticals Corporation; 2017 (accessed 2022 Jan 31). Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/209092s003lbl.pdf
   Google Scholar
• Babcock A, Ali AA, Balkrishnan R, et al. Real-world clinical and economic outcomes associated with palbociclib for HR-positive/HER2 negative metastatic breast cancer: a commentary. J Manag Care Spec Pharm. 2020;26(7):826–831.
   PubMed Web of Science ®Google Scholar
• Beachler DC, de Luise C, Jamal-Allial A, et al. Real-world safety of palbociclib in breast cancer patients in the United States: a new user cohort study. BMC Cancer. 2021;21(1):97.
   PubMed Web of Science ®Google Scholar
• Bui TBV, Burgers DM, Agterof MJ, et al. Real-world effectiveness of palbociclib versus clinical trial results in patients with advanced/metastatic breast cancer that progressed on previous endocrine therapy. Breast Cancer. 2019;13:1178223418823238.
   Web of Science ®Google Scholar
• Cuyun Carter G, Sheffield KM, Gossai A, et al. Real-world treatment patterns and outcomes of abemaciclib for the treatment of HR+, HER2- metastatic breast cancer. Curr Med Res Opin. 2021;37(7):1179–1187.
   PubMed Web of Science ®Google Scholar
• Fountzilas E, Koliou GA, Vozikis A, et al. Real-world clinical outcome and toxicity data and economic aspects in patients with advanced breast cancer treated with cyclin-dependent kinase 4/6 (CDK4/6) inhibitors combined with endocrine therapy: the experience of the hellenic cooperative oncology group. ESMO Open. 2020;5(4):e000774.
   PubMed Web of Science ®Google Scholar
• Gervaso L, Montero AJ, Jia X, et al. Venous thromboembolism in breast cancer patients receiving cyclin-dependent kinase inhibitors. J Clin Oncol. 2019;37(15_suppl):e18184–e18184.
   Web of Science ®Google Scholar
• Harbeck N, Bartlett M, Spurden D, et al. CDK4/6 inhibitors in HR+/HER2- advanced/metastatic breast cancer: a systematic literature review of real-world evidence studies. Future Oncol. 2021;17(16):2107–2122.
   PubMed Web of Science ®Google Scholar
• Kish JK, Ward MA, Garofalo D, et al. Real-world evidence analysis of palbociclib prescribing patterns for patients with advanced/metastatic breast cancer treated in community oncology practice in the USA one year post approval. Breast Cancer Res. 2018;20(1):37.
   PubMed Web of Science ®Google Scholar
• Kristensen KB, Thomsen IMN, Berg T, et al. Dose modifications of ribociclib and endocrine therapy for treatment of ER + HER2- metastatic breast cancer. Breast Cancer Res Treat. 2021;188(3):799–809.
   PubMed Web of Science ®Google Scholar
• Patel U, Lowe Meisel JL, Spencer Barbee MS, et al. The clinical utility of strict laboratory monitoring of CDK 4/6 inhibitors in metastatic breast cancer patients. J Clin Oncol. 2019;37(15_suppl):1062–1062.
   PubMed Web of Science ®Google Scholar
• Varella L, Eziokwu AS, Jia X, et al. Real-world clinical outcomes and toxicity in metastatic breast cancer patients treated with palbociclib and endocrine therapy. Breast Cancer Res Treat. 2019;176(2):429–434.
   PubMed Web of Science ®Google Scholar
• Watson GA, Deac O, Aslam R, et al. Real-world experience of palbociclib-induced adverse events and compliance with complete blood count monitoring in women with hormone receptor-positive/HER2-negative metastatic breast cancer. Clin Breast Cancer. 2019;19(1):e186–e194.
   PubMed Web of Science ®Google Scholar
• Rifkin RM, Medhekar R, Amirian ES, et al. A real-world comparative analysis of carfilzomib and other systemic multiple myeloma chemotherapies in a US community oncology setting. Ther Adv Hematol. 2019;10:2040620718816699.
   Web of Science ®Google Scholar
• Rugo HS, Huober J, Garcia-Saenz JA, et al. Management of abemaciclib-associated adverse events in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: safety analysis of MONARCH 2 and MONARCH 3. Oncologist. 2020;25:1–13.
   PubMed Web of Science ®Google Scholar
• Slamon DJ, Neven P, Chia S, et al. Phase III randomized study of ribociclib and fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: MONALEESA-3. J Clin Oncol. 2018;36(24):2465–2472.
   PubMed Web of Science ®Google Scholar
• Unger JM, Barlow WE, Martin DP, et al. Comparison of survival outcomes among cancer patients treated in and out of clinical trials. J Natl Cancer Inst. 2014;106:dju002.
   PubMedGoogle Scholar
• Diéras V, Rugo HS, Schnell P, et al. Long-term pooled safety analysis of palbociclib in combination with endocrine therapy for HR+/HER2− advanced breast cancer. J Natl Cancer Inst. 2019;111(4):419–430.
   PubMedGoogle Scholar
• Gong J, Cho M, Yu KW, et al. A single institution experience with palbociclib toxicity requiring dose modifications. Breast Cancer Res Treat. 2018;168(2):381–387.
   PubMed Web of Science ®Google Scholar
• Stearns V, Brufsky AM, Verma S, et al. Expanded-access study of palbociclib in combination with letrozole for treatment of postmenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer. Clin Breast Cancer. 2018;18(6):e1239–e1245.
   PubMed Web of Science ®Google Scholar
• Xi J, Oza A, Thomas S, et al. Retrospective analysis of treatment patterns and effectiveness of palbociclib and subsequent regimens in metastatic breast cancer. J Natl Compr Canc Netw. 2019;17(2):141–147.
   PubMed Web of Science ®Google Scholar
• Jahan N, Wongsaengsak S, Rehman S, et al. Relative risk of pneumonitis or interstitial lung disease (ILD) associated with the use of cyclin-dependent kinase inhibitors (CDK4/6i): a systematic review and meta-analysis of phase 3 randomized controlled trials. J Clin Oncol. 2021;39(15_suppl):1072–1072.
   Web of Science ®Google Scholar
• Felip E, Llobera L, Perez-Mana C, et al. New drugs, old toxicities: pneumonitis related to palbociclib - a case report. Breast Care. 2020;15(5):548–552.
   PubMed Web of Science ®Google Scholar
• Greer JA, Amoyal N, Nisotel L, et al. A systematic review of adherence to oral antineoplastic therapies. Oncologist. 2016;21(3):354–376.
   PubMed Web of Science ®Google Scholar
• Lin C, Clark R, Tu P, et al. Breast cancer oral anti-cancer medication adherence: a systematic review of psychosocial motivators and barriers. Breast Cancer Res Treat. 2017;165(2):247–260.
   PubMed Web of Science ®Google Scholar
• Goetz MP, Okera M, Wildiers H, et al. Safety and efficacy of abemaciclib plus endocrine therapy in older patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: an age-specific subgroup analysis of MONARCH 2 and 3 trials. Breast Cancer Res Treat. 2021;186(2):417–428.
   PubMed Web of Science ®Google Scholar
• Rassen JA, Schneeweiss S. Newly marketed medications present unique challenges for nonrandomized comparative effectiveness analyses. J Comp Eff Res. 2012;1(2):109–111.
   PubMed Web of Science ®Google Scholar
• Schneeweiss S, Gagne JJ, Glynn RJ, et al. Assessing the comparative effectiveness of newly marketed medications: methodological challenges and implications for drug development. Clin Pharmacol Ther. 2011;90(6):777–790.
   PubMed Web of Science ®Google Scholar